SCHEMBL17560796

SCHEMBL17560796

Nc1nc(N/N=C/c2cccc(O)c2O)cc(N/N=C/c2cccc(O)c2O)n1.O=Cc1cccc(O)c1O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 10/20 0.52
▸ MEN1 O00255 7/20 0.52
▸ KMT2A Q03164 7/20 0.52
▸ POLB P06746 4/20 0.52
▸ KLF5 Q13887 1/20 0.52
▸ ERN1 O75460 1/20 0.50
▸ NOX4 Q9NPH5 1/20 0.48
▸ MAPT P10636 7/20 0.46
▸ LMNA P02545 6/20 0.46
▸ KDM4E B2RXH2 5/20 0.46
▸ SMN1; SMN2 Q16637 3/20 0.46
▸ L3MBTL1 Q9Y468 3/20 0.46
▸ ALDH1A1 P00352 2/20 0.46
▸ MPI P34949 1/20 0.46
▸ CCR6 P51684 1/20 0.45
▸ NPC1 O15118 3/20 0.44
▸ RAB9A P51151 2/20 0.43
▸ PAX8 Q06710 2/20 0.43
▸ NPSR1 Q6W5P4 2/20 0.43
▸ HCRTR1 O43613 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17560799 1.00 GAA (0.52) GAAMEN1KMT2APOLBKLF5
SCHEMBL19449735 0.94 GAA (0.58) GAAMEN1KMT2APOLBKLF5
SCHEMBL19434700 0.83 KMT2A (0.59) GAAMEN1KMT2APOLBMAPT
SCHEMBL19434701 0.83 KMT2A (0.59) GAAMEN1KMT2APOLBMAPT
SCHEMBL17560967 0.79 KMT2A (0.44) GAAMEN1KMT2APOLBMAPT
SCHEMBL17560970 0.79 KMT2A (0.44) GAAMEN1KMT2APOLBMAPT
SCHEMBL21882648 0.75 MEN1 (0.38) GAAMEN1KMT2APOLBKLF5
SCHEMBL17560842 0.73 MEN1 (0.62) GAAMEN1KMT2APOLBMAPT
SCHEMBL19449736 0.73 KMT2A (0.49) GAAMEN1KMT2APOLBMAPT
SCHEMBL17560996 0.73 LMNA (0.58) GAAMEN1KMT2APOLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11566012-B2 Methods for treating protozoan infections NEOCULI PTY LTD (AU) 2023-01-31 — — US claimed
US-20210009552-A1 METHODS FOR TREATING PROTOZOAN INFECTIONS NEOCULI PTY LTD (AU) 2021-01-14 — — US claimed
US-20170291886-A1 METHODS FOR TREATING PROTOZOAN INFECTIONS NEOCULI PTY LTD (AU) 2017-10-12 — — US claimed
EP-3188722-A1 METHODS FOR TREATING PROTOZOAN INFECTIONS Neoculi Pty Ltd (AU) 2017-07-12 — — EP claimed
WO-2016033635-A1 METHODS FOR TREATING PROTOZOAN INFECTIONS NEOCULI PTY LTD (AU) 2016-03-10 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11566012-B2 Methods for treating protozoan infections DPM1, ABCB11, PIGS GAA 231/4885MEN1 504/4885KMT2A 2912/4885
US-20210009552-A1 METHODS FOR TREATING PROTOZOAN INFECTIONS DPM1, ABCB11, PIGS GAA 231/4885MEN1 504/4885KMT2A 2912/4885
US-20170291886-A1 METHODS FOR TREATING PROTOZOAN INFECTIONS DPM1, ABCB11, PIGS GAA 231/4885MEN1 504/4885KMT2A 2912/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback